Khursheed Azharudin, Khursheed Nuzhat, Rashid Nusrat, Khanday Waheed Ahmad, Hussain Afzal, Alajmi Mohamed F, Amir Samira, Malik Akhtar Hussain, Rather Jahangir Ahmad, Wani Abdul Haleem, Ahmad Jahangir, Hussain Iqbal, Iqbal Prince Firdous, Wani Waseem A
Department of Chemistry, Sri Pratap College M.A. Road Srinagar J&K - 190001 India
Department of Clinical Biochemistry, University of Kashmir Hazratbal Srinagar J&K - 190006 India.
RSC Med Chem. 2025 Jun 24. doi: 10.1039/d5md00323g.
The unanticipated finding of cisplatin's anticancer properties prompted extensive investigations into different platinum-containing complexes as anticancer agents. However, the side effects and resilience of cancerous cells to platinum complexes triggered investigations on non-platinum anticancer complexes. As a result, several non-platinum complexes have been developed. Among these, the anticancer potential of cobalt complexes has been recognized over the past few decades. Inorganic medicinal chemists are fascinated by cobalt complexes, as these complexes interact with cellular proteins and macromolecules, causing cellular disruption and stopping the division, growth and multiplication of cancer cells. Owing to the increasing interest of researchers in the development of anticancer cobalt complexes, this paper critically reviews the developments in the design and development of these complexes. The results of the and investigations of anticancer profiles of cobalt complexes with ligands such as Schiff bases, quinolines, carbonyl groups, polypyridyl ligands, macrocycles, thiosemicarbazones, active pharmaceuticals, natural products, are reviewed. Importantly, the intervention of nanotechnological approaches in amplifying the therapeutic properties of anticancer cobalt complexes is discussed. Besides, the modes of action of anticancer cobalt complexes are highlighted. Moreover, pharmacologically significant cobalt complexes with equal or better anticancer effects than that of standard anticancer agents are identified. Finally, the existing challenges and future perspectives in research on the design and development of anticancer cobalt complexes are discussed.
顺铂抗癌特性的意外发现促使人们对不同的含铂配合物作为抗癌剂进行了广泛研究。然而,癌细胞对铂配合物的副作用和耐受性引发了对非铂抗癌配合物的研究。结果,已经开发出了几种非铂配合物。其中,钴配合物的抗癌潜力在过去几十年中得到了认可。无机药物化学家对钴配合物很感兴趣,因为这些配合物与细胞蛋白质和大分子相互作用,导致细胞破坏并阻止癌细胞的分裂、生长和增殖。由于研究人员对开发抗癌钴配合物的兴趣日益浓厚,本文对这些配合物的设计和开发进展进行了批判性综述。综述了含席夫碱、喹啉、羰基、多吡啶配体、大环化合物、硫代氨基脲、活性药物、天然产物等配体的钴配合物抗癌谱的 和 研究结果。重要的是,讨论了纳米技术方法在增强抗癌钴配合物治疗特性方面的干预作用。此外,还强调了抗癌钴配合物的作用方式。此外,还鉴定出了具有与标准抗癌药物相当或更好抗癌效果的药理学上重要的钴配合物。最后,讨论了抗癌钴配合物设计和开发研究中存在的挑战和未来前景。
Psychopharmacol Bull. 2024-7-8
2025-1
Cochrane Database Syst Rev. 2008-7-16
Autism Adulthood. 2024-12-2
Arch Ital Urol Androl. 2025-6-30
Cochrane Database Syst Rev. 2021-4-19
CA Cancer J Clin. 2025
Angew Chem Int Ed Engl. 2024-11-25
Inorg Chem. 2024-4-1
Dalton Trans. 2024-4-2
Signal Transduct Target Ther. 2024-3-8